Renal affection in gout


Cite item

Full Text

Abstract

The study of the problem of impairment of the kidneys in gout is important because investigation of gout nephropathy specifies the role of hyperuricemia (a known risk factor) in development of renal damage, on the one side, and emphasizes the role of early detection of hyperuricemic genesis of nephropathy allowing prognosis improvement due to administration of uricostatic treatment, on the other side. Earlier data on tubulointerstitial lesion are now supplied with information on essential glomerular damage due to endothelial dysfunction in the presence of insulin resistance often associated with gout.

About the authors

Il'ya Vadimovich Egorov

Email: ilegor@mail.ru

Vladimir Viktorovich Tsurko

I V Egorov

Family Medicine Center "Sofia", Moscow

Family Medicine Center "Sofia", Moscow

V V Tsurko

I.M. Sechenov First Moscow State Medical University, Moscow

I.M. Sechenov First Moscow State Medical University, Moscow

References

  1. Guest S. S. Uric acid and the kidney. In: Nephrology rounds 4. Snell medical communications. 2001. 1-5.
  2. Dykman D., Simon E. E. Hyperuricemia and uric acid nephropathy. Arch. Intern. Med. 1987; 147: 1341-1345.
  3. Кудаева Ф. М., Барскова В. Г., Гордеев А. В. Современные представления о факторах, обусловливающих поражение почек при подагре. Тер. арх. 2005; 5: 90-95.
  4. Kang D. H., Nakagawa T., Feng L. et al. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 2002; 13: 2888-2897.
  5. Mukherjee E., Mukherji D., Jayawardene S. A. et al. Tumor lysis syndrome and acute renal failure an increasing spectrum of presentations. Clin. Nephrol. 2007; 68: 186-189.
  6. Johnson R. J., Segal M. S., Srinivas T. et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J. Am. Soc. Nephrol. 2005; 16: 1909-1919.
  7. Mazzali M., Hughes J., Kim Y. et al. Elevated uric acid increase blood pressure in the rat by a novel crystal-independent mechanisms. Hypertension 2001; 38: 1101-1106.
  8. Fessel W. J. Renal outcomes of gout and hyperuricemia. Am. J. Med. 1979; 67: 74-82.
  9. Jones D. P., Stapleton F. B., Kalwinsky D. et al. Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia. Med. Pediatr. Oncol. 1990; 18: 283-286.
  10. Bingham C., Ellard S. et al. Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor-1 beta gene mutation. Kidney Int. 2003; 63: 1645-1651.
  11. Бунчук Н. В. Подагра. В кн.: Насонова В. А., Бунчук Н. В. (ред.). Ревматические болезни. М.; 1997. 363-374.
  12. Николаев А. Ю. Нарушения пуринового обмена при алкоголизме. В кн.: Моисеев В. С. (ред.). Алкогольная болезнь. М.; 1990. 95-99.
  13. Мухин Н. А., Балкаров И. М. Подагрическая почка. В кн.: Тареева И. Е. Нефрология. М.; 2000. 422-429.
  14. Avram Z., Krishnan E. Hyperuricaemia - where nephrology meets rheumatology? Rheumatology (Oxford) 2008; 47: 960-964.
  15. Чиж А. С. Поражение почек при подагре. В кн.: Чиж А. С. (ред.). Нефрология в терапевтической практике 1998. 437.
  16. Николаев А. Ю., Милованов Ю. С. Нарушения пуринового обмена и подагрическая нефропатия. Лечащий врач 2006; 10: 54-57.
  17. Bhattacharjee S. A brief history of gout. Int. J. Rheum. Dis. 2009; 12: 61-63.
  18. Conger J. D. Acute uric acid nephropathy. Med. Clin. N. Am. 1990; 74: 859-871.
  19. Hess B., Binswanger U. Acute uric acid nephropathy in two gouty patients with moderate hyperuricemia and high urine acidity. J. Molec. Med. 1990; 68: 874-879.
  20. Shekarriz B., Stoller M. L. Uric acid nephrolithiasis: Current concepts and controversies. J. Urol. (Baltimore) 2002; 168: 1307-1312.
  21. Abate N., Chandalia M., Cabo-Chan A. V. et al. The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestation of insulin resistance. Kidney Int. 2004; 65: 386-390.
  22. Asplin J. R. Uric acid stones. Semin. Nephrol. 1996; 16: 412-418.
  23. Лебедева М. В., Балкаров И. М., Мухин Н. А. Ранняя диагностика уратного поражения почек. Тер. арх. 1997; 6: 56-59.
  24. Futrakul P., Yenrudi S., Futrakul N. et al. Tubular function and tubulointerstitial disease. Am. J. Kidney Dis. 1999; 33: 886-891.
  25. Feinfeld D. A., Ansari N., Nuovo M. et al. Tubulointerstitial nephritis associated with gout. Am. J. Kidney Dis. 1999; 33: 3-7.
  26. Emmerson B. T. Chronic lead nephropathy. The diagnostic use of calcium EDTA and the association with gout. Austral. Ann. Med. 1963; 12: 310-317.
  27. Мухин Н. А., Серов В. В., Максимов Н. А. и др. Некоторые особенности гиперурикемического варианта латентного гломерулонефрита. Тер. арх. 1985; 6: 36-43.
  28. Мухин И. В., Николаенко В. Ю. Морфологические изменения почек при подагрическом гломерулонефрите. Нефрология 2004; 8: 73-77.
  29. Dykman D., Simon E. E., Avioli L. V. Hyperuricemia and uric acid nephropathy. Arch. Intern. Med. 1987; 147: 1341-1345.
  30. Ильинский Б. В. Георгий Федорович Ланг. Л.: Наука; 1985.
  31. Reaven G. M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
  32. Avogaro P. Associaziione di iperlidemia, diabete mellito e obesita di medio grado. Acto Diabetol. Lat. 1967; 4: 36-41.
  33. Camus J. Goutte, diabete, hyperlipemie: un trisyndrome metabolique. Rev. Rhum. 1966; 33: 10-14.
  34. Mehnert H., Kuhlmann H. Hypertonie und Diabetes mellitus. Dtsch. Med. J. 1968: 19: 567-571.
  35. Vague J. The degree of masculine differentiation in obesity as a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am. J. Clin. Nutr. 1956; 4: 20-34.
  36. Насонова В. А., Барскова В. Г. Ранние диагностика и лечение подагры - научно обоснованное требование улучшения трудового и жизненного прогноза больных. Науч.-практ. ревматол. 2004; 1: 5-7.
  37. Bloomgarden Z. T. American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome. Diabet. Care 2003; 26: 933-939.
  38. Uric acid as a prognostic marker in acute heart failure - new expectations from an old molecule. Eur. J. Heart Fail. 2007; 9: 437-439.
  39. Kojima S., Sakamoto T., Ishihara M. et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am. J. Cardiol. 2005; 96: 489-495.
  40. Wan-Jing H., Wen-Pin T., Kuang-Hui Y. et al. Association between endothelial dysfunction and hyperuricaemia. Rheumatology 2010; 49: 1929-1934.
  41. Khosla U. M., Zharikov S., Finch J. L. et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005; 67: 1739-1742.
  42. Karbowska A., Boratynska M., Kusztal M. et al. Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transplant. Proc. 2009; 41: 3052-3055.
  43. Kato M., Hisatone I., Tomikura Y. Status of endothelial dependent vasodilatation in patients with hyperuticemia. Am. J. Cardiol. 2005; 96: 1576-1578.
  44. Erdogan D., Gullu H., Caliskan M. et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int. J. Clin. Pract. 2005; 59: 1276-1282.
  45. Mene P., Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J. Hypertens. 2008; 26: 2085-2092.
  46. Nakagawa T., Mazzali M., Kang D.-H. et al. Hyperuricemia causes glomerular hypertrophy in the rats. Am. J. Nephrol. 2003; 23: 2-7.
  47. Tonelli M., Wiebe N., Culleton B. et al. Chronic kidney disease and mortality risk: a systematic review. J. Am. Soc. Nephrol. 2006; 17: 2034-2047.
  48. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. Kidney Dis. 2002; 392 (Suppl. 1): S1-S266.
  49. Edwards N. L. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleveland Clin. J. Med. 2008; 75 (Suppl. 50: S13-S16.
  50. Feig D. I., Kang D. H., Johnson R. J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008; 359: 1811-1821.
  51. Барскова В. Г., Насонова В. А., Якунина И. Я. и др. О тяжести течения женской подагры. Тер. арх. 2005; 5: 58-62.
  52. Тареев Е. М. Гломерулонефриты. В кн.: Клиническая нефрология, 2-е изд. М.: Медицина; 1983; т. 2: 5-99.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies